Bordeaux

• DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI … Recruiting
  2024-513475-41-00 5 2025-02-03 Multiple Sclerosis
• A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy Recruiting
  2023-505320-54-00 4 2025-01-30 Multiple System Atrophy
• A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) an … Recruiting
  2024-512900-20-00 7 2025-01-30 Non-muscle invasive bladder cancer (NMIBC)
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Surgical treatment of large incisional hernia with botulinum toxin A injection: a double-blind randomized controlled trial Recruiting
  2023-504554-35-00 5 2025-01-17 incisional hernia
• An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting
  2024-512161-14-00 3 2025-01-14 Breast Cancer
• ANRS0392s ELDORADO : Phase III, open-label, randomized, multicenter trial EvaLuating the non-inferiority of DORAvirine versus DOlutegravir b … Recruiting
  2023-508626-10-00 5 2025-01-08 HIV-1 infection
• Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting
  2023-509811-98-00 4 2025-01-07 Patients with HER2-positive locally advanced inoperable or metastatic
• Interest of post-operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high-risk of relapse based on … Recruiting
  2023-506350-21-00 4 2025-01-06 Localized, resected, FIGO stage I (2018 classification), uterine leiom
• Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit … Recruiting
  2024-510981-18-00 5 2024-12-12 Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is o
• A Phase 2 study to Evaluate the Safety, Tolerability and Efficacy of Efgartigimod PH20 SC given by prefilled syringe in Kidney Transplant Re … Recruiting
  2023-508180-72-00 4 2024-12-11 Antibody-Mediated Rejection
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k … Recruiting
  2023-510150-17-00 4 2024-12-11 Active, refractory systemic lupus erythematosus (SLE), and active, re
• A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting
  2023-510380-34-00 4 2024-12-10 Diffuse cutaneous systemic sclerosis (dcSSc)
• This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting
  2023-504713-76-00 5 2024-12-03 Dermatitis atopic
• Evaluation of the Safety and Efficacy of Metformin in Steinert's Disease: A Prospective, Multicenter, Randomized, Double Blind, Phase 3 Tria … Recruiting
  2023-507660-39-00 5 2024-12-03 Myotonic dystrophy type 1 (DM1)
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical tr … Recruiting
  2023-508400-38-00 4 2024-11-29 meningioma
• Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous nephropathy - iRITUX Recruiting
  2024-510718-34-00 11 2024-11-29 Membranous nephropathy
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• Short versus long antiplatelet therapy after TAVI Recruiting
  2023-508208-40-00 10 2024-11-21 All adult patients with successful transfemoral trans-aortic valve imp
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• MEPENDAX: Phase I/II study of axitinib (Inlyta®) and oral metronomic etoposide for pediatric children and AYA with refractory/relapsing medu … Recruiting
  2023-509585-38-00 9 2024-11-19 Ependymoma
• Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Pati … Recruiting
  2024-511313-38-00 4 2024-11-17 Soft Tissue Sarcoma

Showing 361–384 of 1,096 trials